UCB traded at 73.64 this Thursday August 11th, decreasing 0.10 or 0.14 percent since the previous trading session. Looking back, over the last four weeks, UCB lost 13.32 percent. Over the last 12 months, its price fell by 24.86 percent. Looking ahead, we forecast UCB to be priced at 71.60 by the end of this quarter and at 65.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
73.64
Daily Change
-0.14%
Yearly
-24.86%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alcon AG 67.24 -0.52 -0.77% 2.91%
Almirall SA 9.81 0.02 0.15% -29.17%
Amarin 1.61 0.08 5.23% -71.45%
argenx SE 364.60 6.10 1.70% 36.45%
Artemis Alpha 318.00 2.82 0.89% -28.70%
AstraZeneca 10,506.00 -312.00 -2.88% 26.59%
Bayer 51.68 -0.22 -0.42% 7.75%
Genmab 2,722.00 139.00 5.38% -7.29%
Galapagos 52.98 0.26 0.49% 6.19%
GRIFOLS 13.84 0.12 0.87% -33.40%
GlaxoSmithKline 1,400.00 -156.60 -10.06% -5.02%
Hikma Pharmaceutical 1,565.00 -46.00 -2.86% -38.48%
Lonza Group 584.00 14.20 2.49% -19.11%
Merck 187.10 -0.70 -0.37% -2.35%
Novartis 81.04 -1.47 -1.78% -5.48%
Orion 46.72 0.32 0.69% 34.25%
Recordati 42.84 0.08 0.19% -24.10%
Roche Holding 310.15 -6.80 -2.15% -15.47%
Sanofi 84.75 -2.92 -3.33% -2.95%
UCB 73.64 -0.10 -0.14% -24.86%
Unibail Rodamco 59.77 0.21 0.35% -20.30%

Indexes Price Day Year
BE20 3840 2.06 0.05% -11.71%
EU100 1268 6.18 0.49% -4.46%

UCB
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.